| First Author | de Paula-Silva M | Year | 2021 |
| Journal | Front Immunol | Volume | 12 |
| Pages | 714138 | PubMed ID | 34603288 |
| Mgi Jnum | J:312694 | Mgi Id | MGI:6785808 |
| Doi | 10.3389/fimmu.2021.714138 | Citation | de Paula-Silva M, et al. (2021) Formyl Peptide Receptors and Annexin A1: Complementary Mechanisms to Infliximab in Murine Experimental Colitis and Crohn's Disease. Front Immunol 12:714138 |
| abstractText | Non-responsiveness to anti-TNF-alpha therapies presents relevant rates in inflammatory bowel disease patients, presenting the need to find biomarkers involved in therapeutic efficacy. Herein, we demonstrate that higher levels of colonic formyl peptide receptor 1 and annexin A1 correlate with histological recovery in Crohn's disease patients under remission. Using the dextran sulfate sodium colitis model in mice, we suggest that infliximab induces annexin A1 expression and secretion in activated intestinal leukocytes. Conversely, this mechanism might stimulate epithelial formyl peptide receptors, inducing wound healing and consequent histological remission. Our data indicate that assessing intestinal expressions of formyl peptide receptors and annexin A1 might provide precious information on the disease activity and responsiveness to infliximab in inflammatory bowel disease patients. |
